AU2002365675B2 - Effectors of innate immunity - Google Patents

Effectors of innate immunity Download PDF

Info

Publication number
AU2002365675B2
AU2002365675B2 AU2002365675A AU2002365675A AU2002365675B2 AU 2002365675 B2 AU2002365675 B2 AU 2002365675B2 AU 2002365675 A AU2002365675 A AU 2002365675A AU 2002365675 A AU2002365675 A AU 2002365675A AU 2002365675 B2 AU2002365675 B2 AU 2002365675B2
Authority
AU
Australia
Prior art keywords
seq
protein
peptide
cells
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002365675A
Other languages
English (en)
Other versions
AU2002365675A1 (en
Inventor
Dawn Bowdish
B Brett Finlay
Robert E W Hancock
Jon-Paul Steven Powers
Carrie Melissa Rosenberger
Monisha Gough Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of AU2002365675A1 publication Critical patent/AU2002365675A1/en
Assigned to THE UNIVERSITY OF BRITISH COLUMBIA reassignment THE UNIVERSITY OF BRITISH COLUMBIA Amend patent request/document other than specification (104) Assignors: UNIVERSITY OF BRITISH COLUMBIA
Application granted granted Critical
Publication of AU2002365675B2 publication Critical patent/AU2002365675B2/en
Priority to AU2007201885A priority Critical patent/AU2007201885A1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
AU2002365675A 2001-12-03 2002-12-02 Effectors of innate immunity Expired AU2002365675B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007201885A AU2007201885A1 (en) 2001-12-03 2007-04-27 Effectors of innate immunity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33663201P 2001-12-03 2001-12-03
US60/336,632 2001-12-03
PCT/CA2002/001830 WO2003048383A2 (fr) 2001-12-03 2002-12-02 Effecteurs d'immunite innee

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007201885A Division AU2007201885A1 (en) 2001-12-03 2007-04-27 Effectors of innate immunity

Publications (2)

Publication Number Publication Date
AU2002365675A1 AU2002365675A1 (en) 2003-06-17
AU2002365675B2 true AU2002365675B2 (en) 2007-04-05

Family

ID=23316965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002365675A Expired AU2002365675B2 (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Country Status (12)

Country Link
EP (1) EP1470249A2 (fr)
JP (1) JP2005536985A (fr)
KR (1) KR20040077669A (fr)
CN (2) CN100357324C (fr)
AU (1) AU2002365675B2 (fr)
CA (1) CA2468907A1 (fr)
HK (1) HK1075677A1 (fr)
IL (1) IL162300A0 (fr)
NZ (2) NZ533721A (fr)
SG (1) SG159382A1 (fr)
WO (1) WO2003048383A2 (fr)
ZA (1) ZA200404919B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7507787B2 (en) 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
MXPA06002828A (es) * 2003-09-12 2006-06-23 Univ British Columbia Efectores de determinacion de inmunidad innata.
WO2006005190A1 (fr) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals Inc. Procede de criblage destine a la protection contre l'infection microbienne
US7638340B2 (en) 2005-06-22 2009-12-29 Seikagu Corporation Method of eliminating reactivity of lipoarabinomannan and application of the same
GB0517090D0 (en) 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
JP2009509552A (ja) * 2005-10-04 2009-03-12 イニメックス ファーマシューティカルズ インコーポレイテッド 先天免疫を調節することによる感染の処置および予防を含む、免疫関連疾患障害の処置および予防のための新規ペプチド
ES2497441T3 (es) 2006-08-21 2014-09-22 The University Of British Columbia Péptidos inmunomoduladores catiónicos pequeños
SG175573A1 (en) * 2006-10-04 2011-11-28 Inimex Pharmaceuticals Inc Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
WO2009057695A1 (fr) * 2007-10-30 2009-05-07 Olympus Corporation Procédé de détection d'un adénome ou d'un cancer par analyse génétique
WO2010026489A1 (fr) * 2008-09-05 2010-03-11 The University Of British Columbia Modulateurs d'immunité innée
EP2346521A4 (fr) * 2008-10-06 2012-06-20 Univ Colorado Regents Peptides et procédés d'utilisation
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
KR20230119130A (ko) 2020-12-14 2023-08-16 리제너론 파마슈티칼스 인코포레이티드 인히빈 서브유닛 베타 e(inhbe) 억제제로 대사 장애 및 심혈관 질환을 치료하는 방법
WO2023063994A1 (fr) * 2021-10-13 2023-04-20 Phenomune, LLC Méthodes de test pour la détermination du phénotype t2r et leurs applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877274A (en) * 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
DE19734161A1 (de) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh SDF-1 - Antagonisten
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Scott et al ,2000, The Journal of Immunology, vol 165: 3358-3365 *

Also Published As

Publication number Publication date
CN101215601A (zh) 2008-07-09
CA2468907A1 (fr) 2003-06-12
EP1470249A2 (fr) 2004-10-27
CN1615368A (zh) 2005-05-11
JP2005536985A (ja) 2005-12-08
HK1075677A1 (en) 2005-12-23
CN100357324C (zh) 2007-12-26
WO2003048383A2 (fr) 2003-06-12
AU2002365675A1 (en) 2003-06-17
NZ533721A (en) 2007-12-21
SG159382A1 (en) 2010-03-30
WO2003048383A3 (fr) 2004-08-05
ZA200404919B (en) 2006-05-31
IL162300A0 (en) 2005-11-20
NZ563261A (en) 2008-08-29
KR20040077669A (ko) 2004-09-06

Similar Documents

Publication Publication Date Title
US7507787B2 (en) Effectors of innate immunity
AU2002365675B2 (en) Effectors of innate immunity
US20070134261A1 (en) Effectors of innate immunity
Hedges et al. γδ T cells respond directly to pathogen-associated molecular patterns
Meyer Interferons and autoimmune disorders
Xu et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity
Zang et al. Aberrant T cell migration toward RANTES and MIP-1α in patients with multiple sclerosis: Overexpression of chemokine receptor CCR5
Vaidya et al. Toll-like receptors and innate antiviral responses
da Silva et al. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-α 2b vs. IFN-β 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor
Schlottmann et al. Prolonged classical NF-κB activation prevents autophagy upon E. coli stimulation in vitro: a potential resolving mechanism of inflammation
US7687454B2 (en) Effectors of innate immunity determination
WO1997006182A1 (fr) Inhibiteurs de l'apoptose
EP1434854B1 (fr) Compositions utiles comme ligands du recepteur de type recepteur 1 des peptides formyles et procedes d'utilisation de celles-ci
Meisch et al. Human β-defensin 3 induces STAT1 phosphorylation, tyrosine phosphatase activity, and cytokine synthesis in T cells
US20070190533A1 (en) Effectors of innate immunity
WO2006069449A1 (fr) Activite immunomodulatoire et antiproliferative independante du recepteur de la chimiokine
AU2007201885A1 (en) Effectors of innate immunity
KR20070033314A (ko) 양이온성 펩티드를 사용한 선천 면역의 자극 방법
WO2001088199A2 (fr) Compositions, trousses et methodes d'identification et de modulation de cellules th1 et th2, et maladies associees
Nagel et al. Identification of genes differentially expressed in T cells following stimulation with the chemokines CXCL12 and CXCL10
JP2009500314A (ja) 遺伝子調節
Wilson et al. Interleukin-16
Natarajan Characterization of chemokine CCL19 in the duck (Anas platyrhynchos)
Finlay et al. Monisha G. Scott, Carrie M. Rosenberger, Michael R. Gold

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT/PATENTEE FROM UNIVERSITY OF BRITISH COLUMBIA TO THE UNIVERSITY OF BRITISH COLUMBIA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired